APPLICATION OF KSHARASUTRA OVER SURGICAL EXCISION OF NEUROFIBROMA (NF1): A CASE REPORT

Neurofibromatosis type 1 (NF1) or Von Recklinghausen's disease is a rare genetic disorder characterized by the development of multiple noncancerous tumors of nerves and skin (neurofibromas). Head and neck neurofibroma are generally located in the soft tissue. Here, a case of a 42-year-old man with NF1 has been presented. The disease started in childhood with the appearance of multiple hyperpigmented skin macules. He has generalized freckling and café-au-lait spots all over the body and cutaneous nodules with multiple sizes. The diagnosis of NF1 was made according to presence of two or more diagnostic criteria of the National Institute of Health Consensus Development Conference. On the basis of symptoms, it was closely related to the Kaphaja Arbuda. Acharya Sushruta mentioned Kshara and Ksharasutra in Arbuda Chikitsa. So, Ksharasutra was tied on the root of one of the neurofibroma size of 4 x 2.5 cm present on medial side of the mid arm. The Fibroma was shed-off completely after 7 days and no recurrence was observed in a follow up at the end of 12 months after application of Ksharasutra.

The Safety of Intravenous Drug Delivery Systems: Update on Current Issues Since the 2009 Consensus Development Conference

This review was prepared in advance of the Third Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems that was held at the W Hotel in Chicago, Illinois, from November 1 through 3, 2018. The purpose of this conference was to evaluate the safety of intravenous (IV) infusion systems used for medication administration. The expert panel of pharmacists, physicians, and nurses updated the findings of the Second Consensus Development Conference in 2009 that reviewed 5 IV drug delivery systems (manufacturer ready to use, outsourced ready to use, point-of-care activated, pharmacy compounded, and nonpharmacy compounded at point of care) with regard to applicability, ease of use, regulatory compliance, cost, safety, and implementation. The Third Consensus Development Conference expanded on previous findings by reviewing proceedings related to new standards, legislation, technologies, and shortage-related challenges related to IV medication administration that have been published since 2009. Invited faculty and audience members participated in revising a preliminary report summarizing these changes during the meeting.